Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
Walter Reed Army institute, pharmaceutical company sign research agreement
August 15th, 2005
The Walter Reed Army Institute of Research (WRAIR), of the U.S. Army Medical Research and Material Command in Silver Spring, Maryland, and Maas BiolAB, LLC announced the signing of their Cooperative Research and Development Agreement (CRADA) to develop cyclosporin neuroprotection in indications relevant to military casualties and Homeland Security. These indications include battlefield traumatic brain injury and military or civilian exposure to nerve agents. Since 2003, Maas BiolAB, under a Material Transfer Agreement with Walter Reed, has provided its cyclosporin neuroprotection formula for severe traumatic brain injury studies. Under the terms of the CRADA, Maas...
Source: Pharma Business Week (2005-08-15)
|
